News & Resources
News & Resources
- HemoShear Appoints Leading Industry Executives to its Scientific Advisory Board - September 1, 2010
Ruffolo and Batchelor Bring Strong Industry Drug Development Expertise
- HemoShear Scientists Profile Genomic Behavior of the Human Artery - July 13, 2010
Results Expected to Lead to Development of Safer, More Effective Treatments of Human Artery Disease
- HemoShear Board Member John L. Brooks III Named Chairman of the Joslin Diabetes Center - June 28, 2010
- HemoShear Technology Used to Discover How Key Protein Plays Important Role in Development of Atherosclerosis - June 18, 2010
Findings Published in a Journal of the American Heart Association
- HemoShear Awarded National Institutes of Health Grant for Atherosclerosis Study - April 14, 2010
Human Surrogate Model will be used to study the disease’s inflammatory onset.
- Brian Wamhoff, Ph.D., Wins 2010 APS New Investigator Award for Cardiovascular Research - March 8, 2010
American Physiological Society Honors HemoShear Co-Founder and Vice-President of Research and Development.
- Dr. Timothy L. Pruett Joins HemoShear LLC’s Scientific Advisory Board - February 10, 2010
Transplant specialist to advise HemoShear in developing advanced models of the human liver for discovery of new drug candidates and study of liver diseases.
- HemoShear, LLC, Launches HepaShear Division - November 9, 2009
HemoShear, LLC, a developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds in the laboratory announces the formation of a new division, HepaShear, to develop an advanced human surrogate model of the liver.
- HemoShear, LLC, Raises $5 Million in Angel Equity Financings - August 1, 2009
HemoShear, LLC, a developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds in the laboratory recently completed $5 million in angel equity financings. The funds will be used to launch commercial applications of its human artery model and to develop a human surrogate liver model for discovery and testing of new drug compounds.
- John L. Brooks III Joins HemoShear, LLC, Board of Managers - April 7, 2009
HemoShear, LLC, a developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds in the laboratory, today announced that John L. Brooks III has joined its Board of Managers.
